New tool aims to help melanoma patients with autoimmune conditions navigate treatment decisions
NCT ID NCT04751396
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare providers. About 125 participants will give feedback through interviews and surveys to improve the tool.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- educational tool
- What this could lead to
- If successful, this tool could help patients with melanoma and autoimmune diseases make more informed decisions about their treatment options.
- What could go wrong
- This is an early-stage study focused on usability, not on treatment outcomes. The tool may not improve decision-making or be widely adopted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 125 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with melanoma or pre-existing autoimmune disease and clinicians
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of melanoma * Diagnosis of pre-existing autoimmune disease * Inflammatory bowel disease * Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist * For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically * Treatment with aminosalicylates, corticosteroids, thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists) * Rheumatoid arthritis * Diagnosis of rheumatoid arthritis by a rheumatologist * Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy * Systemic lupus erythematosus * Diagnosis of systemic lupus erythematosus by a rheumatologist * Psoriasis * Diagnosis of psoriasis by a dermatologist * Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies * Spondyloarthropathies * Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis/spondylitis by a rheumatologist * Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy * Age of 18 years or older * Patients whose physicians had recommended they begin using any of the currently available immune checkpoint inhibitors or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor * E-mail access and computer with Internet access or telephone * Ability to communicate in English or Spanish * CLINICIAN * Prescribed immune checkpoint inhibitors * Are providing care for patients with melanoma * In the clinics at MD Anderson
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Scientists probe why rheumatic pain feels different for everyone
- Mini-Guts in a dish: scientists probe why IBD tissue struggles to heal
- Can taekwondo kicks ease ankylosing spondylitis?
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Ulcerative colitis drugs put under the microscope for hidden clot risk